Regeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying ...
Barchart on MSN21h
Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?Amgen (AMGN) is a biotech company based in California. It specializes in developing treatments for cardiovascular conditions, ...
Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The company’s Phase 3 trial in myasthenia gravis remains on track to ...
EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fightLight Up your Portfolio with Spark:Easily identify ...
New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...
Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...
MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...
The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...
Amgen (NASDAQ:AMGN) shares were on track for its seven straight sessions of gains on Monday, as the stock rose nearly 3% to ...
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).
In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback